Addex Therapeutics Shareholders Endorse Board's Resolutions
Successful AGM for Addex Therapeutics
In a recent ad hoc announcement, Addex Therapeutics, a clinical-stage pharmaceutical company, reported a successful Annual General Meeting (AGM) where shareholders overwhelmingly approved all proposals put forth by the board. This meeting engaged 30.18% of the company's outstanding capital, showcasing a robust participation from stakeholders.
Resolutions Passed by Shareholders
During the meeting, shareholders voted favorably on several key items, including the approval of the 2024 annual report and financial statements. In addition, the compensation report received support in a consultative capacity, alongside the remuneration for board members and executive management. The board members were granted discharge for their activities during the previous business year, illustrating trust in their governance.
Board of Directors Re-elected
Dr. Vincent Lawton continues as chairman and a board member, alongside Dr. Raymond Hill, who retains a position on the board and as a member of the compensation committee. The board also welcomed back Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn, and Dr. Isaac Manke, solidifying a team committed to steering the company ahead.
Auditor and Voting Rights Representative Re-elections
The congregation of shareholders re-elected BDO SA as auditors for the upcoming 2025 business year, ensuring continued oversight of the company's financial practices. Furthermore, Robert P. Briner was re-appointed as the independent voting rights representative, maintaining authority until the next AGM, aimed at upholding transparency in shareholder engagements.
Details Available on Addex’s Website
For shareholders and interested parties seeking more detailed information about the meeting's agenda and outcomes, Addex provides thorough documentation on its official website.
About Addex Therapeutics
Addex Therapeutics is at the forefront of drug development, focusing on creating innovative allosteric modulators aimed at neurological disorders. The company’s leading candidate, dipraglurant, aims to enhance recovery from brain injuries, including instances following strokes and traumatic events. Partnering with Indivior, Addex is also advancing a GABAB PAM drug candidate targeting substance use disorders, which has successfully cleared the necessary IND enabling studies. An independent GABAB PAM program aimed at treating chronic cough is further evidence of Addex's commitment to addressing critical health needs.
Investor Engagement and Future Prospects
Furthermore, Addex holds a 20% equity stake in Neurosterix LLC, a company dedicated to a series of allosteric modulator programs focusing on various neurological challenges. With shares traded under the ticker symbol 'ADXN' on both the SIX Swiss Exchange and NASDAQ, Addex continues to engage with investors, ensuring a clear and transparent dialogue about its ongoing projects and strategic directions.
Contact Information for Inquiries
For further inquiries regarding Addex Therapeutics, stakeholders can reach out to:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: [email protected]
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)20 7318 2955
Email: [email protected]
Frequently Asked Questions
What company held its Annual General Meeting recently?
Addex Therapeutics held its Annual General Meeting with shareholders approving all board proposals.
What key resolutions were passed during the AGM?
The AGM saw approval for the annual report, financial statements, and compensation report, alongside the discharge of board members for their previous year's activities.
Who were re-elected to the board of directors?
Dr. Vincent Lawton, Dr. Raymond Hill, Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn, and Dr. Isaac Manke were re-elected to the board.
Which auditors were re-elected at the AGM?
BDO SA was re-elected as auditors for the 2025 business year.
What is the focus of Addex Therapeutics?
Addex Therapeutics focuses on developing small molecule allosteric modulators to treat neurological disorders.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to [email protected].
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.